Oryzon gets its first Patent in the US
Oryzon to Present at BioEquity Europe 2013 in Stockholm
Oryzon will participate at the 14th International Conference on Alzheimer’s Drug Discovery
Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC’s 3rd Epigenetics in Drug Discovery conference in Boston
ORYZON awarded 1,1 Million EUROS grant to develop its EPIGENETIC LSD1 inhibitors for Acute Leukemia
Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine
06/07/2011
